Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of D-Glutamate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.95 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.95 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.95 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.95 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.95 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.95 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.95 |
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.54 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.54 |
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.54 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.54 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.54 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.54 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.54 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.54 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.54 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.54 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.54 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.54 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Glutamate SCHEMBL176818 | 1.00 | GRM8 (0.95) | GRM8GRM6GRM7GRM4GSR | |
| Glutamic Acid SCHEMBL176819 | 1.00 | GRM8 (0.95) | GRM8GRM6GRM7GRM4GSR | |
| Glutamic Acid SCHEMBL7505530 | 1.00 | GRM8 (0.95) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL16894004 | 1.00 | GRM8 (0.95) | GRM8GRM6GRM7GRM4GSR | |
| Glutamic Acid SCHEMBL16894005 | 1.00 | GRM8 (0.95) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL7505526 | 1.00 | GRM8 (0.95) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL4025168 | 0.97 | GRM8 (0.90) | GRM8GRM6GRM7GRM4GSR | |
| Glutamic Acid SCHEMBL11431055 | 0.97 | GRM8 (0.90) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL2163608 | 0.97 | GRM8 (0.90) | GRM8GRM6GRM7GRM4GSR | |
| Glutamic Acid SCHEMBL7050327 | 0.97 | GRM8 (0.90) | GRM8GRM6GRM7GRM4GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119162266-A | High-yield strategy of porphyrin compound and application thereof | 华东理工大学 | 2024-12-20 | — | — | CN | claimed |
| CN-114989455-A | Composite hydrogel for photocuring cell-loaded 3D printing and preparation method and application thereof | 燕山大学 | 2022-09-02 | — | — | CN | claimed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| WO-2025088147-A1 | THERANOSTIC PSMA-TARGETING LIGANDS FOR THE DIAGNOSIS AND TREATMENT OF PSMA-EXPRESSING CANCERS AND THEIR SOLID PHASE SYNTHESIS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-05-01 | — | — | WO | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-12194573-B2 | Solder paste | SENJU METAL INDUSTRY CO., LTD. (JP) | 2025-01-14 | — | — | US | disclosed |
| CN-119162266-A | High-yield strategy of porphyrin compound and application thereof | 华东理工大学 | 2024-12-20 | — | — | CN | disclosed |
| CN-117946007-A | Curcumin-amino acid methyl ester derivative and preparation method and application thereof | 河北科技大学 | 2024-04-30 | — | — | CN | disclosed |
| EP-4063061-B1 | FLUX AND SOLDER PASTE | SENJU METAL INDUSTRY CO (JP) | 2024-04-24 | — | — | EP | disclosed |
| EP-4063060-B1 | FLUX AND SOLDER PASTE | SENJU METAL INDUSTRY CO (JP) | 2024-04-24 | — | — | EP | disclosed |
| EP-3666787-B1 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2024-02-21 | — | — | EP | disclosed |
| EP-0904271-A4 | 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES | UNIV PRINCETON (US) | 2002-01-23 | — | — | EP | disclosed |
| CN-1278717-A | Hair care compositions comprising optical brighteners and hair conditioning agents | PROCTER & GAMBLE (US) | 2001-01-03 | — | — | CN | disclosed |
| US-6066639-A | ANTITUMOR AGENTS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| EP-0904271-A1 | 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1999-03-31 | — | — | EP | disclosed |
| US-5688771-A | Lipophilic oligopeptides with immunomodulating activity | BIOCHEM PHARMA INC. (CA) | 1997-11-18 | — | — | US | disclosed |
| WO-1997041115-A1 | 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1997-11-06 | — | — | WO | disclosed |
| US-5489583-A | FOR TREATING OR PREVENTING THROMBOSIS | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-06 | — | — | US | disclosed |
| WO-1995009845-A1 | PYRIMIDINYL-GLUTAMIC ACID DERIVATIVES | ELI LILLY AND COMPANY (US) | 1995-04-13 | — | — | WO | disclosed |
| WO-1993020100-A1 | NOVEL LIPOPHILIC OLIGOPEPTIDES WITH IMMUNOMODULATING ACTIVITY | BIOCHEM PHARMA INC. (CA) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | GRIN2D 2415/4885GRIN3B 3020/4885GRIN1 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.